From prompts to production-grade clinical trial analysis.
Monday: 3 core prompts for trial analysis. Tuesday: automated extraction code. Wednesday: team workflows across research, compliance, and data teams. Thursday: complete technical architecture with multi-agent orchestration, ML pipelines, HIPAA compliance, and scaling from 10 to 10,000 trials per month.
Key Assumptions
System Requirements
Functional
- Ingest trial protocols, case reports, lab results, adverse events (PDF, XML, HL7 FHIR)
- Extract structured data: endpoints, demographics, outcomes, safety signals
- Analyze efficacy (primary/secondary endpoints), safety (AE classification), compliance (protocol deviations)
- Generate regulatory reports (CSR sections, safety narratives, statistical summaries)
- Detect data quality issues, missing fields, outliers, protocol violations
- Support multi-study meta-analysis and comparative effectiveness research
- Provide audit trail for all data transformations and AI decisions
Non-Functional (SLOs)
š° Cost Targets: {"per_trial_usd":15,"per_page_usd":0.05,"compute_percent_of_revenue":20}
Agent Layer
planner
L4Decompose trial analysis into subtasks, select tools, route to specialized agents
š§ TaskDecomposer, AgentRouter, PriorityQueue
ā” Recovery: If task decomposition fails ā fallback to template-based plan, If agent unavailable ā queue for retry with backoff, If priority conflict ā escalate to human reviewer
executor
L3Execute trial analysis: extract data, compute endpoints, generate insights
š§ DocumentParser, LLM (Claude/GPT), StatisticalAnalyzer, SafetySignalDetector, ComplianceChecker
ā” Recovery: If extraction fails ā retry with different LLM, If low confidence (<0.7) ā flag for human review, If statistical error ā fallback to manual calculation, If timeout ā save partial results, resume later
evaluator
L2Validate output quality, check completeness, detect anomalies
š§ SchemaValidator, AnomalyDetector, CrossReferencer (vs ClinicalTrials.gov), StatisticalValidator
ā” Recovery: If validation fails ā return gaps to Executor for re-extraction, If anomaly detected ā flag for expert review, continue processing, If schema mismatch ā attempt auto-mapping, fallback to manual
guardrail
L1Enforce HIPAA compliance, redact PHI, check safety policies, audit all actions
š§ PHIDetector (AWS Comprehend Medical), RedactionEngine, PolicyChecker, AuditLogger, ConsentValidator
ā” Recovery: If PHI detected ā block processing until redacted, If policy violation ā halt workflow, notify compliance team, If audit log fails ā retry 3x, escalate to ops, Never proceed without guardrail approval
meta_analysis
L3Aggregate results across multiple trials, perform comparative effectiveness analysis
š§ MetaAnalysisEngine, ForestPlotGenerator, HeterogeneityCalculator, SubgroupAnalyzer
ā” Recovery: If insufficient trials ā return error, suggest minimum N, If high heterogeneity ā flag for sensitivity analysis, If statistical assumptions violated ā use robust methods
report
L2Generate regulatory reports (CSR sections, safety narratives, statistical summaries)
š§ TemplateEngine, NarrativeGenerator (LLM), TableFormatter, PDFGenerator
ā” Recovery: If template error ā fallback to default ICH E3 structure, If narrative generation fails ā use rule-based templates, If formatting error ā export raw data for manual formatting
ML Layer
Feature Store
Update: Daily batch + real-time for urgent safety signals
- ⢠trial_phase_encoded
- ⢠subject_demographics_vector
- ⢠adverse_event_frequency
- ⢠endpoint_effect_size
- ⢠protocol_complexity_score
- ⢠site_performance_metrics
- ⢠drug_mechanism_embedding
Model Registry
Strategy: Semantic versioning (major.minor.patch) + Git SHA
- ⢠TrialExtractionLLM
- ⢠SafetyClassifier
- ⢠EndpointPredictor
- ⢠ComplianceDetector
Observability Stack
Real-time monitoring, tracing & alerting
0 activeDeployment Variants
Startup Architecture
Fast to deploy, cost-efficient, scales to 100 competitors
Infrastructure
Risks & Mitigations
ā ļø LLM hallucination leads to false trial results in regulatory submission
Medium (0.2% rate)ā Mitigation: 4-layer validation (confidence scoring, cross-reference, statistical plausibility, human review). 100% catch rate. Never auto-submit without expert approval.
ā ļø PHI leakage due to incomplete redaction
Low (guardrail agent enforces 100% scan)ā Mitigation: Guardrail agent blocks all processing until PHI scan completes. Dual-layer: AWS Comprehend Medical + custom NER. Quarterly audits by compliance team.
ā ļø Multi-tenant data isolation failure (customer A sees customer B's trials)
Low (VPC isolation + RBAC)ā Mitigation: Network-level isolation (VPC per tenant). Database row-level security. API-level tenant ID validation. Penetration testing quarterly.
ā ļø Model drift degrades accuracy over time (new drug classes, trial designs)
High (pharma evolves rapidly)ā Mitigation: Quarterly model retraining. Real-time drift detection (PSI > 0.25 ā alert). Shadow mode testing before deployment. Rollback policy if accuracy drops >5%.
ā ļø Cost overrun due to LLM API usage (10K trials/mo Ć $15/trial = $150K/mo)
Medium (usage spikes unpredictable)ā Mitigation: Per-tenant rate limits. Cost alerts at 80% budget. Prompt optimization (reduce tokens 30%). Cache repeated queries. Negotiate volume discounts with LLM providers.
ā ļø Vendor lock-in (AWS, Anthropic) limits flexibility
Medium (deep integration)ā Mitigation: Abstract LLM calls behind interface (swap providers without code changes). Use open standards (FHIR, HL7). Terraform for IaC (multi-cloud ready). Quarterly vendor review.
ā ļø Regulatory changes (FDA updates 21 CFR Part 11, HIPAA updates)
Low (changes infrequent but high-impact)ā Mitigation: Dedicated compliance officer. Quarterly regulatory reviews. Modular architecture (isolate compliance logic). Compliance-as-code (automated policy checks).
Evolution Roadmap
Progressive transformation from MVP to scale
Phase 1: MVP (0-3 months)
Phase 2: Scale (3-6 months)
Phase 3: Enterprise (6-12 months)
Complete Systems Architecture
9-layer architecture from ingestion to compliance
Presentation
3 components
API Gateway
4 components
Agent Layer
6 components
ML Layer
5 components
Integration
5 components
Data
4 components
External
4 components
Observability
5 components
Security
5 components
Request Flow - Trial Analysis
Automated data flow every hour
Data Flow - Trial Analysis Pipeline
Key Integrations
EDC Systems (Medidata Rave, Oracle Clinical)
EHR Systems (Epic, Cerner)
AWS Comprehend Medical
ClinicalTrials.gov
FDA FAERS (Adverse Event Reporting)
Security & Compliance
Failure Modes & Recovery
| Failure | Fallback | Impact | SLA |
|---|---|---|---|
| LLM API down (Claude/GPT) | Switch to backup LLM ā Queue for retry ā Manual queue (if all fail) | Degraded latency (30s delay), no data loss | 99.5% (5min downtime/mo) |
| Extraction low confidence (<0.7) | Flag for human review ā Re-extract with different prompt ā Use template-based extraction | Quality maintained (no false positives) | 99.9% (human review SLA: 24hr) |
| PHI detection fails (Comprehend Medical timeout) | Block processing ā Retry 3x ā Escalate to compliance team | Safety first (no PHI leakage) | 100% (zero tolerance for PHI exposure) |
| Database unavailable (RDS outage) | Read from replica ā Cache recent queries (Redis) ā Queue writes for replay | Read-only mode (30min), writes delayed | 99.9% (multi-AZ failover <5min) |
| Audit log write fails | Retry 3x ā Write to backup S3 bucket ā Alert ops | Compliance risk (no audit trail) | 100% (FDA requirement) |
| Agent timeout (processing >10min) | Save partial results ā Resume from checkpoint ā Split into smaller tasks | Degraded latency (retry adds 5min) | 95% complete <5min, 99% <10min |
| Multi-tenant resource contention | Throttle lower-priority tenants ā Spin up additional workers ā Notify affected tenants | Fair queuing (enterprise tenants prioritized) | Per-tenant SLA (enterprise: 99.9%, standard: 99.0%) |
RAG vs Fine-Tuning
Hallucination Detection
Evaluation Framework
Dataset Curation
Agentic RAG
Multi-Model Ensemble
Tech Stack Summary
2026 Randeep Bhatia. All Rights Reserved.
No part of this content may be reproduced, distributed, or transmitted in any form without prior written permission.